Renal or hepatic impairment. Pregnancy & lactation. Childn or adolescent. Ganfort
Adequate control of cardiac failure before starting therapy. History of severe cardiac disease. Asthma, hyperthyroidism, Prinzmetal's angina, severe peripheral & central circulatory disorders, hypotension, diabetes. Patients w/ known risk factors for macular oedema. Remove contact lenses prior to application & reinsert ≥15 min after. Patients w/ dry eyes where the cornea is compromised. Ganfort PF
Active intraocular inflammation (eg, uveitis). Aphakic patients, pseudophakic patients w/ torn posterior lens capsule or w/ known risk factors for macular edema (eg, intraocular surgery, retinal vein occlusions, ocular inflammatory disease & diabetic retinopathy). Potential permanent increased brown iris pigmentation, & hair growth may occur in skin areas w/ Ganfort PF contact. Monitor for IOP changes. Patients w/ inflammatory ocular conditions, neovascular glaucoma, inflammatory glaucoma, angle-closure glaucoma, congenital or narrow-angle glaucoma. Preexisting or history of CV disease (eg, CHD, Prinzmetal's angina & cardiac failure) & hypotension. 1st degree heart block. Severe peripheral circulatory disturbance/disorders (ie, Raynaud's phenomenon). Mild or moderate COPD. History of atopy or severe anaphylactic reactions. Diabetics (especially those w/ labile diabetes). May mask signs of hyperthyroidism & hypoglycemia. Corneal disease. Choroidal detachment may occur. Concomitant use w/ other β-blocking agents & surgical anesth. Remove contact lenses prior to administration & reinsert at least 15 min after instillation. May have negligible influence on the ability to drive or use machines.